- Jiang, W., Zeng, H., Liu, Z., Jin, K., Hu, B., Chang, Y., & Xu, J. (2022): Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients. In Urologic Oncology: Seminars and Original Investigations 40 (4), 166-e15.
- Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., & Ficarra, V. (2017): Renal cell carcinoma. Nature reviews Disease primers, 3(1), 1-19
- Mohebat, H. G., Mohammed, A. E., Nehal, S Z., Taghreed, A. E. & Elbaz, M. (2020): Chromophobe Renal Cell Carcinoma, Oncocytoma and Clear Cell Carcinoma A Compartive Immunohistochemical Study. The Medical Journal of Cairo University, 88(March), 103-110.
- Yamada, Y., Arai, T., Kato, M., Kojima, S., Sakamoto, S., Komiya, A., & Seki, N. (2019): Role of pre-miR-532 (miR-532-5p and miR-532-3p) in regulation of gene expression and molecular pathogenesis in renal cell carcinoma. American Journal of Clinical and Experimental Urology, 7(1), 11.
- Kabaria, R., Klaassen, Z., & Terris, M. K. (2016): Renal cell carcinoma: links and risks. International journal of nephrology and renovascular disease, 9, 45–52.
- Altevogt, P., Sammar, M., Hüser, L., & Kristiansen, G. (2021): Novel insights into the function of CD24: A driving force in cancer. International Journal of Cancer, 148(3), 546-559.
- Fang, X., Zheng, P., Tang, J., & Liu, Y. (2010): CD24: from A to Z. Cellular & molecular immunology, 7(2), 100-103.
- Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016): The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. European urology, 70(1), 93-105.
- Lee, H. J., Kim, D. I., Kwak, C., Ku, J. H., & Moon, K. C. (2008): Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance. Urology, 72(3), 603-607.
- Pallagani, L., Choudhary, G. R., Himanshu, P., Madduri, V. K., Singh, M., Gupta, P., & Sanjeev, M. (2021): Epidemiology and clinicopathological profile of renal cell carcinoma: a review from tertiary care referral centre. Journal of Kidney Cancer and VHL, 8(1), 1.
- Qu, Y., Chen, H., Gu, W., Gu, C., Zhang, H., Xu, J., & Ye, D. (2015): Age-dependent association between sex and renal cell carcinoma mortality: a population-based analysis. Scientific reports, 5(1), 9160.
- Arik, D., Can, C., Dündar, E., Kabukçuoğlu, S., & Paşaoğlu, Ö. (2017): Prognostic significance of CD24 in clear cell renal cell carcinoma. Pathology & Oncology Research, 23, 409-416.
- Godlewski, J., Stefaniak, P., Kiezun, J., & Krazinski, B. E. (2022): DNA polymerase Delta 1 catalytic subunit (POLD1) as a prognostic factor in clear cell renal cell carcinoma patients. in vivo, 36(3), 1188-1194.
- Wu, J., Zhang, P., Zhang, G., Wang, H., Gu, W., Dai, B., & Ye, D. (2017): Renal cell carcinoma histological subtype distribution differs by age, gender, and tumor size in coastal Chinese patients. Oncotarget, 8(42), 71797.
- Zanjani, L. S., Madjd, Z., Abolhasani, M., Rasti, A., Fodstad, O., Andersson, Y., & Asgari, M. (2018). Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma. Biomarkers in Medicine, 12(1), 45-61.
- Droz, D., Zachar, D., Charbit, L., Gogusev, J., Chretein, Y., & Iris, L. (1990): Expression of the human nephron differentiation molecules in renal cell carcinomas. The American journal of pathology, 137(4), 895.
|